<DOC>
	<DOCNO>NCT00959777</DOCNO>
	<brief_summary>The safety , tolerability , pharmacokinetics ( PK ) /pharmacodynamics ( PD ) DA-3031 ( PEG-G-CSF ) follow single dose deliver subcutaneous ( SC ) injection investigate healthy volunteer . PK/PD filgrastim ( Dong-A ) follow repeat dose deliver SC injection investigate healthy volunteer . PK/PD single dose DA-3031 repeat dose filgrastim ( Dong-A ) compare .</brief_summary>
	<brief_title>Pharmacokinetic/Pharmacodynamic ( PK/PD ) Study Evaluating DA-3031 ( PEG-G-CSF ) Filgrastim ( Dong-A ) Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Healthy male subject , 2040 year inclusive weight 6075 kg inclusive Ideal Body Weight ( IBW ) 15 % +15 % inclusive Written inform consent give Willing able comply requirement protocol Hypersensitivity drug ( aspirin , antibiotic ) History presence clinically significant liver kidney disease , gastrointestinal , cardiovascular , respiratory , endocrinal , musculoskeletal , neurologic/psychiatric , hematological , oncological pathology Have history drug abuse , show positive drug abuse urine screen Have participate another clinical study within 2 month prior enter inth study Have persistently drink alcohol stop drinking alcohol study Smokers whose average smoke last 3 month 10 cigarettes/day Are consider ineligible investigator due clinical laboratory result relevant reason</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>